Literature DB >> 6975652

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

M T Lotze, E A Grimm, A Mazumder, J L Strausser, S A Rosenberg.   

Abstract

Human lymphocytes derived from the peripheral blood of patients with a variety of cancers were grown in T-cell growth factor (TCGF) and tested in a 4-hr 51Cr microcytotoxicity assay against fresh and cultured autologous tumor, autologous cultured skin fibroblasts, and autologous fresh peripheral blood lymphocytes. Lymphocytes grown in TCGF caused significant lysis of autologous cultured tumor and fibroblasts but caused little lysis of fresh autologous peripheral blood lymphocytes in all of seven patients tested. This lytic activity against autologous cultured cells was not dependent on the source of serum used in culturing the lymphoid cells or the targets. Lymphoid cells grown in TCGF also were capable of causing selective lysis of fresh autologous tumor cells that had never been in culture in five of nine patients. Lymphoid cells growing in lectin-free TCGF caused selective lysis of autologous tumor in five of seven patients. These observations demonstrate that peripheral lymphoid cells grown in TCGF can be lytic for autologous cultured and autologous fresh tumor compared to the lysis of fresh autologous peripheral blood lymphocytes. The fact that these autoreactive cells, lytic for tumor, may be expanded to large numbers in TCGF suggests a possible role for these cells in studies of the control of the cytotoxic response of activated cells to tumor and possibly in the immunotherapy of tumors as well.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975652

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  124 in total

Review 1.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Authors:  S K Sankhla; J S Nadkarni; S N Bhagwati
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 3.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

4.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

6.  Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro.

Authors:  V Bosnes; H Hirschberg
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

7.  Lysis of colonic epithelial cells by allogeneic mononuclear and lymphokine activated killer cells derived from peripheral blood and intestinal mucosa: evidence against a pathogenic role in inflammatory bowel disease.

Authors:  P R Gibson; E van de Pol; W Pullman; W F Doe
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

Review 8.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

9.  Human spontaneous lymphocyte-mediated cytotoxicity (SLMC) against malignant and normal tissue-derived target cell lines tested in autologous and allogeneic combinations by the microcytotoxicity assay.

Authors:  M Vilien; M Troye-Blomberg; P Perlmann; H Wolf; F Rasmussen
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy.

Authors:  J B Hibbs; C Westenfelder; R Taintor; Z Vavrin; C Kablitz; R L Baranowski; J H Ward; R L Menlove; M P McMurry; J P Kushner
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.